ORIC Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
ORIC Pharmaceuticals, a clinical stage oncology company, announced that CEO Jacob M. Chacko will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 11:15 a.m. PT. The presentation will focus on ORIC's innovative treatments that address therapeutic resistance in cancer, including lead candidates ORIC-533, ORIC-114, and ORIC-944. A live webcast will be available on the company’s investor website, with a replay accessible for 90 days post-event.
- None.
- None.
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob M. Chacko, M.D., chief executive officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 11:15 a.m. PT.
A live webcast of the company presentation will be available through the investor section of the company’s website at www.oricpharma.com. A replay of the webcast will be available for 90 days following the event.
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma, (2) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, and (3) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer. Beyond these three product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on Twitter or LinkedIn.
Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com
FAQ
When will ORIC Pharmaceuticals present at the J.P. Morgan Healthcare Conference?
What is the focus of ORIC Pharmaceuticals' presentation at the conference?
How can I watch the ORIC Pharmaceuticals presentation?
What are the lead product candidates of ORIC Pharmaceuticals?
Is there a replay available for the ORIC Pharmaceuticals presentation?
